Kura Oncology (KURA) Accumulated Expenses (2010 - 2026)

Kura Oncology (KURA) has 17 years of Accumulated Expenses data on file, last reported at $10.5 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $10.5 million, up 45.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.5 million (up 45.91% YoY), and the FY2025 annual result was $61.7 million, up 252.39% from the prior year.
• Accumulated Expenses retreated to $10.5 million in Q1 2026 per KURA's latest filing, from $61.7 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $61.7 million in Q4 2025 and troughed at $4.5 million in Q1 2022.
• A 5-year average of $12.5 million and a median of $9.1 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses climbed 12.05% in 2022, then surged 252.39% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $10.3 million in 2022, then gained by 27.7% to $13.2 million in 2023, then jumped by 33.11% to $17.5 million in 2024, then surged by 252.39% to $61.7 million in 2025, then sank by 83.04% to $10.5 million in 2026.
• Business Quant data shows KURA's Accumulated Expenses at $10.5 million in Q1 2026, $61.7 million in Q4 2025, and $14.6 million in Q3 2025.